Thursday, June 24, 2010

New Tri-Staple System From Covidien

Covidien employees discuss the company's philosophy and objectives.Leading healthcare product maker Covidien (COV: 41.68 -0.30 -0.71%)announced the global launch of its novel technology platform for surgical stapling. The state-of-the-art technology, dubbed “Tri-Staple”, has been designed to revolutionize endoscopic stapling. The Tri-Staple platform enables surgeons to use surgical staplers in a broader range of laparoscopic procedures.
Covidien introduced the Endo GIA staple system on June 23, 2010 at the annual meeting of the American Society of Metabolic & Bariatric Surgeons (ASMBS) in Las Vegas. The company will launch additional stapling products based on the Tri-Staple technology over the next 12 months.
Staples are used to close different types of wounds in surgical settings. Although a myriad variety of stapling tools are currently available on the market for endoscopic stapling, they have limitations. Currently, surgeons face the problem of choosing from multiple stapler cartridge sizes to ensure proper stapling for different types of tissues. Moreover, they have to apply significant force in each firing resulting in fatigue after several stapling.         
The Endo GIA stapling system, which is being developed using the Tri-Staple technology, enables surgeons to overcome these problems. Its lightweight stapler handle requires significantly less firing force while stapling and provides greater control. Besides, Endo GIA simplifies cartridge selection as it can be used in a broader range of tissue thicknesses.
Ireland-based Covidien is a leading global healthcare products company that develops and markets medical solutions for better patient outcomes. Covidien operates four business segments: Medical Devices, Imaging Solutions, Pharmaceutical Products, and Medical Supplies. The company’s core medical device business faces stiff competition from Johnson & Johnson (JNJ: 59.1762 -0.0638 -0.11%), Becton Dickinson (BDX: 69.66 -0.39 -0.56%) and C.R. Bard(BCR: 79.26 -0.34 -0.43%).
Covidien boasts a well diversified product and technology portfolio. The company remains committed to rolling out new products and technologies, focusing on faster-growing products and markets, and boosting market share in core segments through investments in sales and marketing infrastructure. Tri-Staple represents a significant addition to Covidien’s proprietary technology line-up.

No comments: